Chisato M Yamazaki - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Chisato M Yamazaki

Showing results (11-20 of 16) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 16 results.

Nature Communications|June 11, 2021

Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistanceChisato M Yamazaki, Aiko Yamaguchi, Yasuaki Anami, et al.

The Journal of Biological Chemistry|February 18, 2006

Specific recognition of the collagen triple helix by chaperone HSP47. II. The HSP47-binding structural motif in collagens and related proteinsTakaki Koide, Yoshimi Nishikawa, Shinichi Asada, et al.

Molecular Cancer Therapeutics|March 7, 2025

177Lu-Labeled Antibody-Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid TumorsAiko Yamaguchi, Chisato M Yamazaki, Yasuaki Anami, et al.

Antibody Therapeutics|April 14, 2026

Affinity-optimized TROP2 antibodies support potent antitumor activity in antibody-drug conjugatesAiko Yamaguchi, Junping Hong, Leike Li, et al.

Molecular Cancer Therapeutics|July 6, 2022

An Enzymatically Cleavable Tripeptide Linker for Maximizing the Therapeutic Index of Antibody-Drug ConjugatesSummer Y Y Ha, Yasuaki Anami, Chisato M Yamazaki, et al.

Journal of Controlled Release : Official Journal of the Controlled Release Society|June 15, 2015

A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosisKazuki N Sugahara, Pablo Scodeller, Gary B Braun, et al.

Pageof 2

Search research articles

Showing results (11-20 of 16) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 16 results.

Nature Communications|June 11, 2021

Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistanceChisato M Yamazaki, Aiko Yamaguchi, Yasuaki Anami, et al.

The Journal of Biological Chemistry|February 18, 2006

Specific recognition of the collagen triple helix by chaperone HSP47. II. The HSP47-binding structural motif in collagens and related proteinsTakaki Koide, Yoshimi Nishikawa, Shinichi Asada, et al.

Molecular Cancer Therapeutics|March 7, 2025

177Lu-Labeled Antibody-Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid TumorsAiko Yamaguchi, Chisato M Yamazaki, Yasuaki Anami, et al.

Antibody Therapeutics|April 14, 2026

Affinity-optimized TROP2 antibodies support potent antitumor activity in antibody-drug conjugatesAiko Yamaguchi, Junping Hong, Leike Li, et al.

Molecular Cancer Therapeutics|July 6, 2022

An Enzymatically Cleavable Tripeptide Linker for Maximizing the Therapeutic Index of Antibody-Drug ConjugatesSummer Y Y Ha, Yasuaki Anami, Chisato M Yamazaki, et al.

Journal of Controlled Release : Official Journal of the Controlled Release Society|June 15, 2015

A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosisKazuki N Sugahara, Pablo Scodeller, Gary B Braun, et al.

Pageof 2